A randomized phase II trial of postoperative adjuvant therapy with imatinib for 1 Year versus 6 months in patients with gastrointestinal stromal tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2014
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 26 Jan 2013 Interim results presented at the 2013 Gastrointestinal Cancers Symposium.
- 21 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 18 Dec 2007 New trial record.